CLINICAL TRIALS PROFILE FOR TICLID
✉ Email this page to a colleague
All Clinical Trials for TICLID
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01823185 ↗ | Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy | Unknown status | Dammam Central Hospital | Phase 4 | 2013-03-01 | Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications. However, clopidogrel is ineffective in certain patients due to genetic mutation in CYP2C19 gene a specific enzyme in the liver required for metabolism of clopidogrel. Therefore, the purpose of this study is to test these patients genetically at bedside and prescribe an alternative drug such as Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) if they are carriers of the allele 2 or 3 of the mutated gene. |
| NCT01823185 ↗ | Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy | Unknown status | King Fahad Armed Forces Hospital | Phase 4 | 2013-03-01 | Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications. However, clopidogrel is ineffective in certain patients due to genetic mutation in CYP2C19 gene a specific enzyme in the liver required for metabolism of clopidogrel. Therefore, the purpose of this study is to test these patients genetically at bedside and prescribe an alternative drug such as Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) if they are carriers of the allele 2 or 3 of the mutated gene. |
| NCT01823185 ↗ | Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy | Unknown status | Dammam University | Phase 4 | 2013-03-01 | Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications. However, clopidogrel is ineffective in certain patients due to genetic mutation in CYP2C19 gene a specific enzyme in the liver required for metabolism of clopidogrel. Therefore, the purpose of this study is to test these patients genetically at bedside and prescribe an alternative drug such as Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) if they are carriers of the allele 2 or 3 of the mutated gene. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TICLID
Condition Name
Clinical Trial Locations for TICLID
Clinical Trial Progress for TICLID
Clinical Trial Phase
Clinical Trial Sponsors for TICLID
Sponsor Name
